Compare Stocks: QNCX, KZIA, INO, and COYA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
COYA Coya Therapeutics	$4.81 +1.7%	$4.69	$3.71 ▼ $7.75	$112.83M	0.58	144,774 shs	88,689 shs
INO Inovio Pharmaceuticals	$1.16 -4.1%	$1.12	$0.56 ▼ $2.72	$119.94M	1.61	2.59 million shs	2.91 million shs
KZIA Novogen	$9.27 -2.1%	$12.14	$4.86 ▼ $17.40	$120.22M	2.26	288,963 shs	128,651 shs
QNCX Quince Therapeutics	$29.20 -4.8%	$29.83	$15.10 ▼ $909.98	$29.70M	1.33	19,802 shs	68,379 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
COYA Coya Therapeutics	0.00%	-5.31%	+5.71%	-17.92%	-17.78%
INO Inovio Pharmaceuticals	0.00%	-1.69%	-14.71%	-4.92%	-51.05%
KZIA Novogen	0.00%	-3.13%	-23.77%	-30.04%	+35.33%
QNCX Quince Therapeutics	0.00%	-5.81%	-4.42%	+69.47%	-90.99%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
COYA Coya Therapeutics	$4.81 +1.7%	$4.69	$3.71 ▼ $7.75	$112.83M	0.58	144,774 shs	88,689 shs
INO Inovio Pharmaceuticals	$1.16 -4.1%	$1.12	$0.56 ▼ $2.72	$119.94M	1.61	2.59 million shs	2.91 million shs
KZIA Novogen	$9.27 -2.1%	$12.14	$4.86 ▼ $17.40	$120.22M	2.26	288,963 shs	128,651 shs
QNCX Quince Therapeutics	$29.20 -4.8%	$29.83	$15.10 ▼ $909.98	$29.70M	1.33	19,802 shs	68,379 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
COYA Coya Therapeutics	0.00%	-5.31%	+5.71%	-17.92%	-17.78%
INO Inovio Pharmaceuticals	0.00%	-1.69%	-14.71%	-4.92%	-51.05%
KZIA Novogen	0.00%	-3.13%	-23.77%	-30.04%	+35.33%
QNCX Quince Therapeutics	0.00%	-5.81%	-4.42%	+69.47%	-90.99%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
COYA Coya Therapeutics	2.71	Moderate Buy	$15.33	218.78% Upside
INO Inovio Pharmaceuticals	2.75	Moderate Buy	$3.17	172.99% Upside
KZIA Novogen	2.67	Moderate Buy	$28.80	210.68% Upside
QNCX Quince Therapeutics	2.62	Moderate Buy	$206.71	607.93% Upside

Current Analyst Ratings Breakdown

Latest QNCX, KZIA, INO, and COYA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/1/2026	QNCX Quince Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold
9/29/2026	QNCX Quince Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
9/29/2026	QNCX Quince Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
9/25/2026	COYA Coya Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/24/2026	QNCX Quince Therapeutics	Rodman & Renshaw Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$70.00
9/24/2026	QNCX Quince Therapeutics	Rodman & Renshaw Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$70.00
9/22/2026	QNCX Quince Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform
9/22/2026	QNCX Quince Therapeutics	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$77.00
9/15/2026	COYA Coya Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$16.00
9/10/2026	KZIA Novogen	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$40.00
9/1/2026	KZIA Novogen	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$34.00 ➝ $40.00

(Data available from 10/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
COYA Coya Therapeutics	$7.95M	14.19	N/A	N/A	$2.06 per share	2.33
INO Inovio Pharmaceuticals	$60K	1,999.07	N/A	N/A	$0.36 per share	3.22
KZIA Novogen	$1.23M	97.75	N/A	N/A	($5.34) per share	-1.74
QNCX Quince Therapeutics	N/A	N/A	N/A	N/A	($128.18) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
COYA Coya Therapeutics	-$21.23M	-$1.07	N/A	N/A	N/A	-270.22%	-52.05%	-46.34%	11/11/2026 (Estimated)
INO Inovio Pharmaceuticals	-$84.95M	-$0.91	N/A	N/A	N/A	N/A	-669.94%	-73.97%	11/10/2026 (Estimated)
KZIA Novogen	-$13.41M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
QNCX Quince Therapeutics	-$83.98M	-$156.71	N/A	N/A	N/A	N/A	N/A	-133.84%	11/11/2026 (Estimated)

Latest QNCX, KZIA, INO, and COYA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	QNCX Quince Therapeutics	-$28.02	-$12.31	+$15.71	-$12.31	N/A	N/A
8/12/2026	Q2 2026	INO Inovio Pharmaceuticals	-$0.2167	-$0.07	+$0.1467	-$0.07	$0.53 million	N/A
8/11/2026	Q2 2026	COYA Coya Therapeutics	-$0.3457	-$0.28	+$0.0657	-$0.28	$0.13 million	$0.24 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
COYA Coya Therapeutics	N/A	N/A	N/A	N/A	N/A
INO Inovio Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
KZIA Novogen	N/A	N/A	N/A	N/A	N/A
QNCX Quince Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
COYA Coya Therapeutics	N/A	13.40	13.40
INO Inovio Pharmaceuticals	N/A	1.00	1.00
KZIA Novogen	N/A	N/A	N/A
QNCX Quince Therapeutics	N/A	14.52	14.52

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
COYA Coya Therapeutics	39.75%
INO Inovio Pharmaceuticals	26.79%
KZIA Novogen	30.89%
QNCX Quince Therapeutics	30.75%

Insider Ownership

Company	Insider Ownership
COYA Coya Therapeutics	6.10%
INO Inovio Pharmaceuticals	1.70%
KZIA Novogen	1.00%
QNCX Quince Therapeutics	5.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
COYA Coya Therapeutics	8	23.46 million	22.03 million	Not Optionable
INO Inovio Pharmaceuticals	112	103.40 million	101.64 million	Optionable
KZIA Novogen	6	12.97 million	12.84 million	No Data
QNCX Quince Therapeutics	38	1.02 million	960,000	Optionable

QNCX, KZIA, INO, and COYA Headlines

Recent News About These Companies

Zacks Research Upgrades Quince Therapeutics (NASDAQ:QNCX) to Hold

October 3 at 6:03 AM | americanbankingnews.com

Quince Therapeutics Maps LAM-001 Trials, With BOS Data Due in 2027

October 2 at 6:02 AM | americanbankingnews.com

Leerink Partners Reaffirms Their Buy Rating on Quince Therapeutics (QNCX)

October 1 at 8:54 AM | theglobeandmail.com

Quince Therapeutics, Inc. (QNCX) Discusses LAM-001 Clinical Progress in Pulmonary Hypertension and Bronchiolitis Obliterans Syndrome Transcript

September 28, 2026 | seekingalpha.com

Quince Therapeutics (NASDAQ:QNCX) Research Coverage Started at Rodman & Renshaw

September 27, 2026 | americanbankingnews.com

Rodman & Renshaw initiates coverage of Quince Therapeutics with a buy

September 24, 2026 | msn.com

Quince Therapeutics stock falls 3.83 percent on Nasdaq

September 24, 2026 | ad-hoc-news.deA

Quince Therapeutics (NASDAQ:QNCX) Stock Rating Upgraded by Citizens Jmp

September 24, 2026 | americanbankingnews.com

Quince Therapeutics stock prepares for LAM-001 KOL event as shares trade below recent highs

September 19, 2026 | ad-hoc-news.deA

Quince Therapeutics to Host Virtual KOL Event to Discuss the Current Treatment Landscape for PH-ILD and BOS and the Role for LAM-001 as a Potential Therapeutic Option on ...

September 17, 2026 | finance.yahoo.com

Quince Therapeutics to Host Virtual KOL Event to Discuss the Current Treatment Landscape for PH-ILD and BOS and the Role for LAM-001 as a Potential Therapeutic Option on September 28, 2026

September 17, 2026 | globenewswire.com

Quince Therapeutics to Participate in September 2026 Investor Conferences

September 3, 2026 | quiverquant.comQ

Quince Therapeutics to Participate in September 2026 Investor Conferences

September 3, 2026 | globenewswire.com

Quince Therapeutics Announces Planned Presidential Leadership Transition

August 27, 2026 | tipranks.com

Quince Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Update

August 14, 2026 | globenewswire.com

Quince Therapeutics

July 6, 2026 | fool.com

Quince Therapeutics Stock Short Interest Report | NASDAQ:QNCX | Benzinga

July 2, 2026 | benzinga.com

Quince Therapeutics Appoints Recognized Leaders in Pulmonary Medicine to Scientific Advisory Board

June 30, 2026 | globenewswire.com

Quince Therapeutics, Inc. (QNCX) Shareholder/Analyst Call Prepared Remarks Transcript

June 11, 2026 | seekingalpha.com

Quince Therapeutics Inc. (QNCX) Presents Positive Phase 2a Data for LAM-001 Inhaled Therapy

June 2, 2026 | insidermonkey.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

QNCX, KZIA, INO, and COYA Company Descriptions

Coya Therapeutics NASDAQ:COYA

$4.81 +0.08 (+1.69%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$4.81 0.00 (0.00%)

As of 10/2/2026 07:30 PM Eastern

Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a low-dose interleukin 2 Treg-enhancing biologic, which is in Phase 2 clinical trial for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an antigen directed Treg-derived exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis. The company was incorporated in 2020 and is headquartered in Houston, Texas.

Inovio Pharmaceuticals NASDAQ:INO

$1.16 -0.05 (-4.13%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$1.17 +0.01 (+0.86%)

As of 10/2/2026 07:58 PM Eastern

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia; INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial; INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.

Novogen NASDAQ:KZIA

$9.27 -0.20 (-2.11%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$9.62 +0.35 (+3.82%)

As of 10/2/2026 04:37 PM Eastern

Kazia Therapeutics Limited operates as an oncology-focused biotechnology company. The company's lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.

Quince Therapeutics NASDAQ:QNCX

$29.20 -1.48 (-4.82%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$29.42 +0.22 (+0.75%)

As of 10/2/2026 07:30 PM Eastern

Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest QNCX, KZIA, INO, and COYA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest QNCX, KZIA, INO, and COYA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

QNCX, KZIA, INO, and COYA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

QNCX, KZIA, INO, and COYA Company Descriptions

Coya Therapeutics NASDAQ:COYA

Inovio Pharmaceuticals NASDAQ:INO

Novogen NASDAQ:KZIA

Quince Therapeutics NASDAQ:QNCX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest QNCX, KZIA, INO, and COYA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest QNCX, KZIA, INO, and COYA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

QNCX, KZIA, INO, and COYA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

QNCX, KZIA, INO, and COYA Company Descriptions

Coya Therapeutics NASDAQ:COYA

Inovio Pharmaceuticals NASDAQ:INO

Novogen NASDAQ:KZIA

Quince Therapeutics NASDAQ:QNCX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools